Brand Name | Status | Last Update |
---|---|---|
nexavar | New Drug Application | 2023-08-28 |
sorafenib | ANDA | 2024-12-11 |
sorafenib tosylate | ANDA | 2024-07-26 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
renal cell carcinoma | EFO_0000376 | D002292 | — |
hepatocellular carcinoma | — | D006528 | C22.0 |
thyroid neoplasms | EFO_0003841 | D013964 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 7 | 29 | 12 | 2 | 21 | 70 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 7 | 15 | 6 | 1 | 12 | 39 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 17 | 6 | 1 | 12 | 38 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 16 | 6 | 1 | 12 | 37 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 17 | 8 | 2 | — | 1 | 25 |
Lung neoplasms | D008175 | — | C34.90 | 6 | 9 | 3 | — | — | 17 |
Non-small-cell lung carcinoma | D002289 | — | — | 7 | 7 | 4 | — | — | 16 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 9 | 1 | — | 1 | 13 |
Melanoma | D008545 | — | — | 2 | 4 | 1 | — | — | 7 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 2 | 1 | — | 2 | 5 |
Thyroid diseases | D013959 | — | E00-E07 | — | 2 | 1 | — | 2 | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 7 | 9 | — | — | — | 11 |
Myeloid leukemia | D007951 | — | C92 | 5 | 7 | — | — | — | 9 |
Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 6 | — | — | — | 8 |
Myelodysplastic syndromes | D009190 | — | D46 | 5 | 6 | — | — | — | 7 |
Preleukemia | D011289 | — | — | 4 | 5 | — | — | — | 6 |
Colorectal neoplasms | D015179 | — | — | 3 | 3 | — | — | — | 5 |
Syndrome | D013577 | — | — | 3 | 4 | — | — | — | 5 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 3 | — | — | — | 5 |
Glioblastoma | D005909 | EFO_0000515 | — | 2 | 3 | — | — | — | 5 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 3 | — | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | — | — | — | — | 2 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
Digestive system neoplasms | D004067 | — | — | 1 | — | — | — | — | 1 |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
Acinar cell carcinoma | D018267 | — | — | 1 | — | — | — | — | 1 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | — | — | — | — | 1 |
Carcinoid tumor | D002276 | — | D3A.00 | 1 | — | — | — | — | 1 |
Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
Oligodendroglioma | D009837 | EFO_0000631 | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Meningeal neoplasms | D008577 | EFO_0003851 | C70 | — | — | — | — | 1 | 1 |
Meningeal carcinomatosis | D055756 | EFO_1001012 | — | — | — | — | — | 1 | 1 |
Meningitis | D008581 | EFO_0000584 | G03 | — | — | — | — | 1 | 1 |
Barrett esophagus | D001471 | EFO_0000280 | K22.7 | — | — | — | — | 1 | 1 |
Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Drug common name | Sorafenib |
INN | sorafenib |
Description | Sorafenib is a member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group. It has a role as an antineoplastic agent, an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor, a tyrosine kinase inhibitor, an angiogenesis inhibitor, an anticoronaviral agent and a ferroptosis inducer. It is a pyridinecarboxamide, a member of monochlorobenzenes, an aromatic ether, a member of (trifluoromethyl)benzenes and a member of phenylureas. |
Classification | Small molecule |
Drug class | rapidly accelerated fibrosarcoma (RAF) kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1 |
PDB | — |
CAS-ID | 284461-73-0 |
RxCUI | — |
ChEMBL ID | CHEMBL1336 |
ChEBI ID | 50924 |
PubChem CID | 216239 |
DrugBank | DB00398 |
UNII ID | 9ZOQ3TZI87 (ChemIDplus, GSRS) |